Erkan Baloglu
36Patents
12h-index
21Co-inventors
77Inventor score
Filing activity: Aug 30, 2002 → Aug 23, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9096543B2 | Nuclear transport modulators and uses thereof | Emerging Cross-Sectional Technologies | 30 | Active |
| US9266843B2 | Nuclear transport modulators and uses thereof | Emerging Cross-Sectional Technologies | 28 | Active |
| US9585874B2 | Nuclear transport modulators and uses thereof | Emerging Cross-Sectional Technologies | 24 | Active |
| US9861614B2 | Nuclear transport modulators and uses thereof | Emerging Cross-Sectional Technologies | 24 | Active |
| US9738624B2 | Nuclear transport modulators and uses thereof | Chemistry; Metallurgy | 24 | Active |
| US10058535B2 | Nuclear transport modulators and uses thereof | Emerging Cross-Sectional Technologies | 21 | Active |
| US10202366B2 | Methods of promoting wound healing using CRM1 inhibitors | Chemistry; Metallurgy | 19 | Active |
| US10407405B2 | Nuclear transport modulators and uses thereof | Chemistry; Metallurgy | 17 | Active |
| US10335393B2 | Nuclear transport modulators and uses thereof | Emerging Cross-Sectional Technologies | 17 | Active |
| US7186851B2 | Facile method for synthesizing baccatin III compounds | Chemistry; Metallurgy | 16 | Expired |
| US7667054B2 | Cytotoxic agents comprising new taxanes | Human Necessities | 14 | Active |
| US7598290B2 | Cytotoxic agents comprising new C-2 modified taxanes | Human Necessities | 14 | Active |
| US8981084B2 | Oxadiazole HDAC inhibitors | Chemistry; Metallurgy | 12 | Active |
| US6828319B2 | Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof | Emerging Cross-Sectional Technologies | 11 | Expired |
| US10526295B2 | Nuclear transport modulators and uses thereof | Chemistry; Metallurgy | 11 | Active |
| US10709706B2 | Nuclear transport modulators and uses thereof | Chemistry; Metallurgy | 10 | Active |
| US7414073B2 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | Emerging Cross-Sectional Technologies | 8 | Expired |
| US11124493B2 | Nuclear transport modulators and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US9856241B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Chemistry; Metallurgy | 6 | Active |
| US8901156B2 | Compounds and methods | Emerging Cross-Sectional Technologies | 6 | Active |
| US7495114B2 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7390898B2 | Cytotoxic agents containing novel potent taxanes and their therapeutic use | Emerging Cross-Sectional Technologies | 6 | Expired |
| US9938258B2 | Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof | Chemistry; Metallurgy | 5 | Active |
| US6956035B2 | Isoquinoline derivatives and methods of use thereof | Chemistry; Metallurgy | 5 | Expired |
| US9994558B2 | Multicyclic compounds and methods of using same | Chemistry; Metallurgy | 5 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.